Medical Cannabis giant Nuuvera Inc. has today announced that it has acquired ASG Pharma, a high-capacity Maltese GMP laboratory.

"ASG Pharma, one of the few GMP labs in Malta, is expected to be one of Nuuvera's hubs for the production and distribution of oil-based medical cannabis products to the emerging European medical cannabis market," a company statement read.

Nuuvera describes itself as "a global cannabis company with a vision."

 Nuuvera's CEO, Lorne Abony, said "It is clear that Malta specifically and the European Union generally intend to make consumer protection a priority, and this approach aligns perfectly with our vision to create a centre of excellence in Malta for the production and distribution of pharmaceutical grade cannabis products. To that end, ASG Pharma will adhere to the highest international standards for processing and extraction, distribution and security protocols."

Through its subsidiary, ARA Avanti RX Analytics, Nuuvera is the only international medical cannabis company that has a standalone Health Canada GMP approved facility that is authorized to conduct commercial scale activities with respect to cannabis and other cannabinoids.

Through its acquisition of ASG Pharma, Nuuvera will bring this expertise to Malta, the statement read.

Antonio Costanzo, Nuuvera's Head of International Development, said "The ASG Pharma acquisition is one in a series of deals which will continue to increase Nuuvera's global footprint in the medical cannabis industry. We will continue to build on our strong Canadian base with strategic international operations and partners in order to provide the consumer with the highest quality medical cannabis at a competitive price."